Bull
$23.01
Scenario price
$18.500
-0.109 (-0.59%)At close
Ares Capital Corporation is a specialty finance company focused on providing direct loans and other investments in private middle market companies in the United States. The Company invests primarily in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position), and second lien senior secured loans. In addition to senior secured loans, it also invests in subordinated debt, which in some cases includes an equity component, and preferred equity. It also may invest up to 30% of its portfolio in non-qualifying assets. Its investment activities are focused on industries, such as software and services, health care services, commercial and professional services, financial services, commercial and professional services, insurance services, energy, food and beverage and others. The Company is externally managed by Ares Capital Management LLC (investment adviser).
Ares Capital Corp (ARCC) is currently priced at $18.64, which is a 4.3% discount to its book value of $19.35. The forward P/E ratio is 10.03, indicating potential for growth, but the recent increase in the nonaccrual rate from 2% to 2.4% poses a risk to future earnings. Given these factors, it may be wise to hold off on buying until after the upcoming earnings report on October 27, 2026, to reassess the situation based on performance and market reaction.
UBS
$21
2026-09-01
UBS
2026-09-01
Price Target
$21
Keefe Bruyette
$20
2026-07-30
Keefe Bruyette
2026-07-30
Price Target
$20
JPMorgan
$19
2026-07-02
JPMorgan
2026-07-02
Price Target
$19
Wells Fargo
$19
2026-06-12
Wells Fargo
2026-06-12
Price Target
$19
B. Riley
$20
2026-04-29
B. Riley
2026-04-29
Price Target
$20
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Ares Capital Acquires MidCap Financial in $2.6 Billion Deal

Ares Capital Declares Q4 2026 Dividend and Reports Q3 Financials

Ares Capital to Acquire MidCap Financial Investment Corporation in $2.6 Billion Deal

Ares Capital Declares Q4 2026 Dividend of $0.48 per Share

Realty Income's Dividend Stability vs. Market Underperformance
Ares Capital Corporation is a specialty finance company focused on providing direct loans and other investments in private middle market companies in the United States. The Company invests primarily in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position), and second lien senior secured loans. In addition to senior secured loans, it also invests in subordinated debt, which in some cases includes an equity component, and preferred equity. It also may invest up to 30% of its portfolio in non-qualifying assets. Its investment activities are focused on industries, such as software and services, health care services, commercial and professional services, financial services, commercial and professional services, insurance services, energy, food and beverage and others. The Company is externally managed by Ares Capital Management LLC (investment adviser). It operates in the Financials sector.
Ares Capital Corp (ARCC) is currently priced at $18.64, which is a 4.3% discount to its book value of $19.35. The forward P/E ratio is 10.03, indicating potential for growth, but the recent increase in the nonaccrual rate from 2% to 2.4% poses a risk to future earnings. Given these factors, it may be wise to hold off on buying until after the upcoming earnings report on October 27, 2026, to reassess the situation based on performance and market reaction.
14 analysts cover ARCC: 10 rate it Buy, 4 Hold and 0 Sell. The average price target is 21.75.

$ARCC Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.46, down -8.00% YoY • Reported revenue of $763M, down -2.43% YoY
Show moreThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.